Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Operating Expenses (2016 - 2025)

Seres Therapeutics' Operating Expenses history spans 11 years, with the latest figure at $22.8 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 21.74% year-over-year to $22.8 million; the TTM value through Sep 2025 reached $103.8 million, down 19.86%, while the annual FY2024 figure was $121.3 million, 37.82% down from the prior year.
  • Operating Expenses for Q3 2025 was $22.8 million at Seres Therapeutics, down from $24.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $76.9 million in Q2 2023 and bottomed at -$4.4 million in Q4 2022.
  • The 5-year median for Operating Expenses is $37.0 million (2023), against an average of $41.1 million.
  • The largest annual shift saw Operating Expenses crashed 107.81% in 2022 before it soared 937.27% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $56.7 million in 2021, then plummeted by 107.81% to -$4.4 million in 2022, then skyrocketed by 937.27% to $37.0 million in 2023, then dropped by 22.12% to $28.8 million in 2024, then fell by 20.84% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Operating Expenses are $22.8 million (Q3 2025), $24.9 million (Q2 2025), and $27.2 million (Q1 2025).